SOPHiA GENETICS chair sells shares, exercises options

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported both option exercises and share sales in late June.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported both option exercises and share sales in late June. On June 29–30, he sold a total of 83,679 Ordinary Shares in multiple open‑market transactions at prices including $6.30, $6.0215, $6.00 and $5.8670 per share, under a pre‑arranged Rule 10b5‑1(c) trading plan.

He also exercised share options to acquire 63,479 Ordinary Shares at an exercise price of $3.16 per share, converting previously granted options into stock. After these transactions, he directly holds 3,581,293 Ordinary Shares and continues to hold 4,646,057 derivative stock options across remaining grant tranches, indicating a substantial ongoing exposure to the company’s equity despite the sales.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider Camblong Jurgi

Role Executive Chairman

Sold 83,679 shs ($507K)

Approx. gross sale proceeds $507K

Approx. exercise cost $201K

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	45,419	$0.00	$0.00
Exercise	Ordinary Shares	45,419	$3.16	$144K
Sale	Ordinary Shares	45,419	$6.1439	$279K
Sale	Ordinary Shares	19,650	$6.0215	$118K
Sale	Ordinary Shares	200	$6.30	$1K
Exercise	Share Option (Right to Buy)	18,060	$0.00	$0.00
Exercise	Ordinary Shares	18,060	$3.16	$57K
Sale	Ordinary Shares	18,060	$5.867	$106K
Sale	Ordinary Shares	350	$6.00	$2K

Holdings After Transaction: Share Option (Right to Buy) — 4,581 contracts (Direct); Ordinary Shares — 3,581,293 shares (Direct)

Footnotes (6)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.10 to $6.30, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.03, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The share options are fully vested and exercisable.
5. F5. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,691,476 derivative stock options across all remaining grant tranches with varying exercise prices.
6. F6. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,646,057 derivative stock options across all remaining grant tranches with varying exercise prices.

Key Figures

Shares sold: 83,679 Ordinary Shares Exercise shares: 63,479 Ordinary Shares Sale prices: $6.30, $6.0215, $6.00, $5.8670 per share +3 more

6 metrics

Shares sold 83,679 Ordinary Shares Open-market sales on June 29–30, 2026

Exercise shares 63,479 Ordinary Shares Shares acquired via option exercises

Sale prices $6.30, $6.0215, $6.00, $5.8670 per share Reported individual transaction prices

Option exercise price $3.16 per share Exercise price of share options converted

Shares held after 3,581,293 Ordinary Shares Direct holdings following reported transactions

Remaining stock options 4,646,057 derivative stock options Aggregate options remaining after exercises

Key Terms

Rule 10b5-1(c), weighted average price, share options, derivative stock options

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

share options financial

"The share options are fully vested and exercisable."

Share options are contracts that give someone the right, but not the obligation, to buy a company’s stock at a predetermined price for a limited time—think of them like a coupon to purchase shares later at a set price. They matter to investors because when exercised they increase the number of outstanding shares (dilution), can change management incentives and company value, and represent a potential future claim on profits or equity.

derivative stock options financial

"holds an aggregate total of 4,646,057 derivative stock options across all remaining grant tranches"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SOPHiA GENETICS (SOPH) shares did Jurgi Camblong sell?

Jurgi Camblong sold 83,679 Ordinary Shares of SOPHiA GENETICS SA. These were executed in several open‑market transactions on June 29–30 at various prices around $6 per share, according to the reported Form 4 transactions and related footnotes.

At what prices were the SOPH shares sold by Jurgi Camblong?

The reported sales occurred at prices including $6.30, $6.0215, $6.00 and $5.8670 per share. Footnotes also note weighted‑average sale prices from ranges of $6.10–$6.30 and $6.00–$6.03, executed across multiple individual trades.

What share options did Jurgi Camblong exercise in this SOPH Form 4?

He exercised share options for a total of 63,479 Ordinary Shares at an exercise price of $3.16 per share. These fully vested, exercisable options were converted into Ordinary Shares in two tranches linked to the reported non‑derivative M‑code transactions.

How many SOPHiA GENETICS shares does Jurgi Camblong hold after the transactions?

After the reported trades, he directly holds 3,581,293 Ordinary Shares. Footnotes further state he retains 4,646,057 derivative stock options across remaining grant tranches, showing a large continuing economic interest in SOPHiA GENETICS SA equity.

Were Jurgi Camblong’s SOPH share sales made under a Rule 10b5-1 plan?

Yes. A footnote specifies the transactions were made under a duly adopted Rule 10b5‑1(c) trading plan. Such pre‑arranged plans schedule trades in advance, meaning the timing of these sales was determined ahead of market conditions.

What does the Form 4 reveal about remaining SOPH stock options held by Jurgi Camblong?

Footnotes note that, following the latest exercise, he holds 4,646,057 derivative stock options across all remaining grant tranches. These options carry varying exercise prices and represent significant additional potential exposure to SOPHiA GENETICS SA shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/29/2026		M		18,060(1)	A	$3.16	3,619,553	D
Ordinary Shares	06/29/2026		S		18,060(1)	D	$5.867	3,601,493	D
Ordinary Shares	06/29/2026		S		350(1)	D	$6	3,601,143	D
Ordinary Shares	06/30/2026		M		45,419(1)	A	$3.16	3,646,562	D
Ordinary Shares	06/30/2026		S		45,419(1)	D	$6.1439(2)	3,601,143	D
Ordinary Shares	06/30/2026		S		19,650(1)	D	$6.0215(3)	3,581,493	D
Ordinary Shares	06/30/2026		S		200(1)	D	$6.3	3,581,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$3.16	06/29/2026		M			18,060(1)	(4)	11/29/2028	Ordinary Shares	18,060	$0	50,000(5)	D
Share Option (Right to Buy)	$3.16	06/30/2026		M			45,419(1)	(4)	11/29/2028	Ordinary Shares	45,419	$0	4,581(6)	D

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.10 to $6.30, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.03, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The share options are fully vested and exercisable.

5. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,691,476 derivative stock options across all remaining grant tranches with varying exercise prices.

6. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,646,057 derivative stock options across all remaining grant tranches with varying exercise prices.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)